Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 501 - 525 of 1181 in total
LY2811376 has been used in trials studying the basic science of Alzheimer's Disease.
Investigational
Experimental
Torcetrapib (CP-529414, Pfizer) was developed to treat hypercholesterolemia but its development was halted in 2006 when phase III studies showed excessive mortality in the treatment group receiving a combination of atorvastatin and the study drug.
Investigational
Buparlisib has been used in trials studying the treatment and basic science of Lymphoma, Metastases, Lung Cancer, Solid Tumors, and Breast Cancer, among others.
Investigational
Mk 0657 has been used in trials studying the treatment of Major Depressive Disorder.
Investigational
Eplivanserin has been used in trials studying the treatment of Sleep, Insomnia, Chronic Pain, Fibromyalgia, and Primary Insomnia, among others.
Investigational
Cebranopadol has been used in trials studying the treatment of Pain, Neoplasms, and Chronic Pain.
Investigational
Henagliflozin has been used in trials studying the treatment of Type 2 Diabetes.
Investigational
Brivanib is under investigation for the treatment of HepatoCellular Carcinoma. Brivanib has been investigated for the treatment of Solid Tumors, Hepato Cellular Carcinoma (HCC), and Metastatic Colorectal Cancer (MCRC).
Investigational
Dilmapimod has been used in trials studying the treatment and diagnostic of Nerve Trauma, Inflammation, Pain, Neuropathic, Arthritis, Rheumatoid, and Coronary Heart Disease, among others. Dilmapimod (SB-681323) is a p38 MAP-kinase inhibitor that has potential uses in inflammatory conditions such as RA (Rheumatoid Arthritis). Previous p38 MAP-kinase inhibitors have been...
Investigational
Mubritinib has been used in trials studying the treatment of Lung Neoplasm, Renal Neoplasm, Breast Neoplasm, Ovarian Neoplasm, and Pancreatic Neoplasm.
Investigational
Olitigaltin has been investigated for the treatment of Idiopathic Pulmonary Fibrosis.
Investigational
Transfluthrin is under investigation in clinical trial NCT02394522 (Spatial Repellent Products for Control of Vector Borne Diseases - Malaria - Zambia (SR-M-ZM)).
Investigational
Ridogrel is a dual action drug useful for the prevention of systemic thrombo-embolism and as an adjunctive agent to thrombolytic therapy in acute myocardial infarction. However, there currently are no clinical indications for preferential use of ridogrel over aspirin.
Experimental
Displaying drugs 501 - 525 of 1181 in total